A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults

← catalyst calendar

NCT07578636

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Basic science

Enrollment

9actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-05-18

actual

When the study began enrolling

Primary completion

2026-07-02

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-08-17

estimated

The whole study's end, after follow-up

First posted

2026-05-11

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-28

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Male Volunteers

Interventions

Drug: Oral [14C] PF-07799544
Drug: Oral Unlabeled PF-07799544
Drug: IV [14C] PF-07799544

Primary outcomes

what the primary-completion date above is the date OF

Total recovery (%) of radioactivity in urine, feces and vomitus (if any), expressed as a percent of total oral radioactive dose administered.

measured Period 1 pre-dose to maximum days 15

Metabolic profiling/identification and determination of relative abundance of [14C]PF-07799544 and the metabolites of PF-07799544 in plasma, urine and feces, if possible.

measured Period 1 pre-dose to maximum days 15

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed